Durgical
EN
Open the app

Connective tissue disease–associated interstitial lung disease

Lung scarring or inflammation caused by autoimmune diseases such as scleroderma, rheumatoid arthritis or myositis. Early screening and treatment help.

Updated

What it is

Interstitial lung disease that develops in a person with a systemic autoimmune rheumatic disease, such as systemic sclerosis, rheumatoid arthritis, idiopathic inflammatory myopathy, Sjögren disease, lupus or mixed connective tissue disease. It may precede, follow or appear with the joint, skin or muscle features.

Who gets it

A leading cause of death in systemic sclerosis and a major one in rheumatoid arthritis and myositis. It is found on CT in roughly half of people with systemic sclerosis and in up to a third of those with antisynthetase antibodies or rheumatoid arthritis; many cases are mild and found on screening. Women predominate overall, but rheumatoid arthritis–ILD is commoner in older men who smoke.

Causes

  • Systemic sclerosis, especially the diffuse form with anti-topoisomerase I (anti-Scl-70) antibodies
  • Rheumatoid arthritis, particularly in seropositive older male smokers
  • Idiopathic inflammatory myopathies: antisynthetase syndrome (anti-Jo-1) and anti-MDA5 dermatomyositis
  • Sjögren disease, systemic lupus erythematosus and mixed connective tissue disease
  • Interstitial pneumonia with autoimmune features: autoimmune signs that do not meet criteria for a single disease

Risk factors

  • Diffuse cutaneous systemic sclerosis and anti-Scl-70 antibodies
  • High-titre rheumatoid factor or anti-CCP antibodies, older age, male sex and smoking in rheumatoid arthritis
  • Antisynthetase and anti-MDA5 antibodies in myositis
  • Early years after the onset of the rheumatic disease
  • Gastro-oesophageal reflux and oesophageal dysmotility (systemic sclerosis)

Pathophysiology

Systemic autoimmunity (autoantibodies, autoreactive T and B cells) → injury to the alveolar epithelium and capillary endothelium → lymphocytic inflammation and cytokines that recruit and activate fibroblasts → a pattern that depends on the disease: mainly cellular and inflammatory (NSIP, organizing pneumonia) or mainly fibrotic (fibrotic NSIP in systemic sclerosis; UIP, the most common pattern only in rheumatoid arthritis) → restriction, low DLCO and hypoxaemia → extra injury from aspiration due to oesophageal disease (systemic sclerosis) and from the drugs used for the rheumatic disease.

Classification

  • By underlying disease: systemic sclerosis, rheumatoid arthritis, myositis, Sjögren, lupus, mixed connective tissue disease
  • By pattern: nonspecific interstitial pneumonia (most common overall), usual interstitial pneumonia, organizing pneumonia, lymphocytic interstitial pneumonia, diffuse alveolar damage
  • By extent and course: limited or extensive; stable or progressive pulmonary fibrosis
  • Rapidly progressive ILD (classically anti-MDA5 dermatomyositis)

Symptoms and signs

  • Exertional breathlessness, sometimes hidden by joint or muscle disease that limits activity
  • Dry cough
  • Bibasal velcro crackles
  • Extrapulmonary clues: Raynaud phenomenon, skin thickening, sclerodactyly, synovitis, proximal muscle weakness, 'mechanic's hands', heliotrope rash or Gottron papules, sicca symptoms
  • Fever and arthritis in antisynthetase syndrome

Diagnosis

Clinical
Every new diagnosis of systemic sclerosis, myositis and other high-risk rheumatic disease is screened for ILD; every new ILD is examined for signs of connective tissue disease. A joint rheumatology–pulmonology–radiology discussion decides the diagnosis and treatment.
Tests
Autoantibody profile: antinuclear antibodies, anti-Scl-70, anticentromere, rheumatoid factor, anti-CCP, anti-Ro/La, anti-RNP, myositis panel (anti-Jo-1 and other antisynthetase antibodies, anti-MDA5); creatine kinase. Spirometry, lung volumes and DLCO at baseline and every few months; six-minute walk with oximetry. Bronchoscopy with lavage mainly to exclude infection.
Imaging
High-resolution CT is the screening and diagnostic test: NSIP pattern (basal ground glass and fine reticulation with subpleural sparing), UIP pattern, or organizing pneumonia. A dilated, air-filled oesophagus suggests systemic sclerosis. Echocardiography screens for pulmonary hypertension.

Differential diagnosis

Which rheumatic disease is behind the ILD?

DiseaseCluesAntibodyUsual lung pattern
Systemic sclerosisRaynaud, thick skin on the fingers, reflux, dilated oesophagus on CTAnti-Scl-70 (topoisomerase I)Fibrotic NSIP at the bases
Rheumatoid arthritisOlder male smoker, symmetrical small-joint arthritisRheumatoid factor, anti-CCPUIP most often, then NSIP
Antisynthetase syndrome (inflammatory myopathy)Proximal weakness, mechanic's hands, arthritis, fever, RaynaudAnti-Jo-1 and other antisynthetase antibodiesNSIP with organizing pneumonia
Anti-MDA5 dermatomyositisSkin ulcers, painful palmar papules, little or no weaknessAnti-MDA5Rapidly progressive ILD
Sjögren diseaseDry eyes and mouth, parotid swellingAnti-Ro (SSA), anti-La (SSB)NSIP; lymphocytic interstitial pneumonia with cysts

Goal of treatment

Find ILD early, stop or slow progression with immunosuppression and antifibrotics, treat the underlying disease and avoid infections and drug toxicity.

Treatment

Medical
Immunosuppression for clinically significant or progressive disease: mycophenolate is first choice in systemic sclerosis–ILD; azathioprine, tocilizumab, rituximab or cyclophosphamide according to the disease and severity.
Medical
Systemic corticosteroids are useful in myositis and organizing pneumonia patterns but are used sparingly in systemic sclerosis, where they can trigger scleroderma renal crisis.
Medical
Antifibrotic therapy (nintedanib, and pirfenidone in some cases) when fibrosis keeps progressing despite treatment; anti-MDA5 rapidly progressive ILD needs early combined intensive therapy.
Rehabilitation
Pulmonary rehabilitation, oxygen for hypoxaemia, smoking cessation, vaccination, prophylaxis against Pneumocystis with intense immunosuppression, and treatment of reflux.
Surgical
Lung transplantation in selected patients with end-stage disease and controlled extrapulmonary disease.
Follow-up
Regular lung function, oximetry and CT when needed; echocardiography for pulmonary hypertension; monitoring blood counts and liver tests on immunosuppressants.

Complications

  • Progressive pulmonary fibrosis and chronic respiratory failure
  • Pulmonary hypertension
  • Opportunistic infections from immunosuppression
  • Acute exacerbation of ILD
  • Lung cancer
  • Drug toxicity

Common traps

  • No joint or skin disease means it cannot be CTD-ILD: the lung can come first, especially in antisynthetase syndrome; test autoantibodies in every new ILD
  • High-dose corticosteroids are the safe first step in every CTD-ILD: in systemic sclerosis they can trigger scleroderma renal crisis; mycophenolate is the usual first choice there
  • Anticentromere is the lung antibody of scleroderma: anti-Scl-70 predicts ILD, while anticentromere (limited disease) points to pulmonary hypertension
  • New infiltrates on methotrexate mean the ILD is progressing: first exclude infection (including Pneumocystis) and drug toxicity
  • Little muscle weakness means mild lung disease: anti-MDA5 dermatomyositis has little or no weakness but can cause rapidly progressive, often fatal ILD

Prognosis

Generally better than idiopathic pulmonary fibrosis, except for UIP-pattern rheumatoid arthritis–ILD and anti-MDA5 rapidly progressive ILD, which can be fatal within months. Extensive disease on CT, a low or falling FVC and DLCO, and pulmonary hypertension predict worse survival.

Test yourself

Think of the answer, then tap the question to see it.

Which antibody in systemic sclerosis carries the highest risk of interstitial lung disease?

Anti-topoisomerase I (anti-Scl-70), usually with diffuse cutaneous disease; anticentromere is linked to pulmonary hypertension instead.

Which connective tissue disease most often shows a UIP pattern on CT?

Rheumatoid arthritis; most other connective tissue diseases show nonspecific interstitial pneumonia.

Why are high-dose corticosteroids avoided in systemic sclerosis–ILD?

They can trigger scleroderma renal crisis (acute kidney injury with malignant hypertension).

Which myositis antibody is linked to rapidly progressive, often fatal ILD?

Anti-MDA5, often with skin ulcers, little or no muscle weakness (amyopathic dermatomyositis).

A 45-year-old woman has 3 months of dyspnoea, fever, proximal weakness and cracked skin on the sides of her fingers; CK is high and CT shows basal ground glass. Which antibody, and what treatment?

Anti-Jo-1 (antisynthetase syndrome): myositis, mechanic's hands and NSIP or organizing pneumonia. After excluding infection, immunosuppression (corticosteroids plus a steroid-sparing agent).

Add to my cards (5)

Why it happens

Connections

Educational information, not medical advice. For any symptom, see a health professional.

Sources: Connective Tissue Disease–Associated Interstitial Lung Disease (StatPearls (NCBI Bookshelf), 2026); Systemic Sclerosis (Scleroderma) (StatPearls (NCBI Bookshelf), 2024).

← All conditions

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.